Kenneth Gordon to Risk Assessment
This is a "connection" page, showing publications Kenneth Gordon has written about Risk Assessment.
Connection Strength
0.302
-
Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. J Eur Acad Dermatol Venereol. 2018 Nov; 32(11):1940-1949.
Score: 0.095
-
Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol. 2012 May; 66(5):742-51.
Score: 0.060
-
From laboratory to clinic: rationale for biologic therapy. Dermatol Clin. 2004 Oct; 22(4):371-7, vii-viii.
Score: 0.037
-
Evolution of biologic therapies for the treatment of psoriasis. Skinmed. 2003 Sep-Oct; 2(5):286-94.
Score: 0.034
-
Association of psoriasis and psoriatic arthritis with osteoporosis and pathological fractures. J Am Acad Dermatol. 2017 Jun; 76(6):1045-1053.e3.
Score: 0.022
-
The inpatient burden of psoriasis in the United States. J Am Acad Dermatol. 2016 Jul; 75(1):33-41.
Score: 0.021
-
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011 Jul; 65(1):137-74.
Score: 0.014
-
A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol. 2007 Apr; 56(4):598-603.
Score: 0.011
-
Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis. Arch Dermatol. 2005 Jun; 141(6):683-7.
Score: 0.010